

### **OPEN ACCESS**

EDITED BY

Chi Pui Pang,

The Chinese University of Hong Kong, China

REVIEWED BY

Elisabetta Lampugnani, Giannina Gaslini Institute (IRCCS), Italy Friedrich Lersch, Insel Gruppe AG, Switzerland Emily Wong,

Hong Kong Eye Hospital, Hong Kong SAR,

\*CORRESPONDENCE

Ke Min

⋈ keminyk@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Children and Health, a section of the journal Frontiers in Pediatrics

RECEIVED 22 November 2022 ACCEPTED 17 January 2023 PUBLISHED 16 February 2023

### CITATION

Weijuan Z, Zonghuan L, Qian W, Xizhi D, Bin J and Min K (2023) Sub-Tenon's bupivacaine injection is superior to placebo for pediatric strabismus surgery: A meta-analysis. Front. Pediatr. 11:1105186.

doi: 10.3389/fped.2023.1105186

### COPYRIGHT

© 2023 Weijuan, Zonghuan, Qian, Xizhi, Bin and Min. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use,

distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Sub-Tenon's bupivacaine injection is superior to placebo for pediatric strabismus surgery: A meta-analysis

Zeng Weijuan<sup>1†</sup>, Li Zonghuan<sup>2†</sup>, Wang Qian<sup>1</sup>, Deng Xizhi<sup>1</sup>, Jiang Bin<sup>1</sup> and Ke Min<sup>1\*</sup>

<sup>1</sup>Department of Ophthalmology, Zhongnan Hospital of Wuhan University, Wuhan, China, <sup>2</sup>Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, China

**Background:** The effect of post-operation sub-Tenon's bupivacaine injection for pediatric strabismus surgery is controversial. The objective of this meta-analysis is to compare the outcome of sub-Tenon injection of bupivacaine and placebo duringstrabismus surgery.

**Methods:** We searched the databases (Pubmed, Cochrane library and EMBASE) and reference lists systematically. Randomized controlled trials (RCTs) comparing sub-Tenon's bupivacaine and placebo injection for pediatric strabismus surgery were included. The methodological quality was evaluated by the Cochrane risk of bias (ROB) tool. Outcome measurements were pain score, oculocardiac reflex (OCR), additional drug consumption and related complications. RevMan 5.4 was used for the statistical analysis and graph preparation. For the outcomes that are not suitable for statistical analysis, descriptive analysis was performed.

**Results:** A total of 5 RCTs with 217 patients were finally identified and analyzed. Sub-Tenon's bupivacaine injection showed pain relief within 30 min after operation. But with the extension of time, the analgesic effect gradually disappeared at 1 h. It can reduce the incidence of OCR, vomiting and supplementary drug requirements. However, in terms of nausea, there is no difference between the two groups.

**Conclusion:** Sub-Tenon's bupivacaine injection can relieve short-term postoperative pain, reduce the incidence of OCR and vomiting, and reduce the use of supplementary drugs in strabismus surgery.

KEYWORDS

sub-Tenon's injection, bupivacaine, strabismus surgery, meta-analysis, pain

# Introduction

Strabismus surgery is one of the most common ophthalmic operations in children. The cumulative incidence of strabismus at age 7 years was 2.5% in Denmark (1). During the perioperative period, strabismus surgery has an incidence of complications including oculocardiac reflex (OCR), pain and postoperative nausea and vomiting (PNAV).

The OCR is generally defined as a 20% decrease of heart rate or a new arrhythmia during ocular operation. The incidence of OCR during ophthalmic surgery ranges from 32% to 90%, and it is also frequent during strabismus surgery (2). Moreover, the OCR is often accompanied by PNAV, with an incidence of 46%–85% (3, 4). Because opioids and NSAIDs should be used with caution in children, ocular local anesthesia is often adopted as an auxiliary means of postoperative analgesia in pediatric ophthalmic surgery under general anesthesia

In recent years, sub-Tenon's block is a widely used local anesthesia technique for ocular operations (5). Local anesthetic is injected between the Tenon capsule and sclera to anesthetize the short and long ciliary nerves (6). Children with sub-Tenon's block during retinal and cataract surgeries experience reduced postoperative pain and lower analgesic

requirements. It is also reported that this technique can reduce perioperative pain and undesirable side effects during pediatric strabismus surgery (7).

In recent years, several RCTs have compared sub-Tenon's bupivacaine injection with placebo injection for strabismus surgery, but the results are not consistent. Therefore, we conducted this study to evaluate the effect of sub-Tenon's injection of bupivacaine in strabismus surgery.

# **Methods**

The meta-analysis was conducted in accordance with PRISMA guidelines. The completed PRISMA checklist was uploaded as supplementary files (Supplementary Table S1).

# Including and excluding criteria

The including and excluding criteria was based on PICOS principle (patient, intervention, comparison, outcome and study design). Including criteria: (i) P: pediatric patients diagnosed with strabismus; (ii) I and C: the patients were treated by surgery and sub-Tenon's bupivacaine/placebo injection were performed; (iii) O: at least one outcome (pain score, oculocardiac reflex, additional drug consumption and related complications) was (were) reported; (iv) S: only RCTs were included. No restriction of publication language was set.

The excluding criteria were as the follows: (i): the number of cases less than 10; (ii): the study included both children and adults patients simultaneously and the exact data of pediatric group could not be retrieved.

### Search strategy

Databases including Pubmed, Cochrane library and Embase were systematically searched. RCTs comparing sub-Tenon's bupivacaine injection and placebo injection for pediatric strabismus surgery were included. Medical Subject Headings together with the free words/terms ("sub-Tenon's", "subtenon's", "bupivacaine", "squint" and "strabismus") were used. The reference lists were also screened and checked for additional studies. The time range of literature retrieval is from the establishment of the database to March 1, 2022.

### Data extraction

The titles and abstracts were screened successively. The unrelated papers were deleted according to the including criteria. The full text of the remaining studies was obtained and checked rigorously. The two authors independently screened the literatures according to the inclusion and exclusion criteria. When there was divergence, the supervisor evaluated and made the decision.

Data were extracted from the included studies, including general information, such as first author, year of publication, country, sample size, age range of included patients, gender ratio, intervention and control measures, study design, etc. At the same time, the outcomes of the literature results were included. If the relevant outcome did not provide specific values, we calculated it from other provided relevant data. Otherwise, only descriptive analysis was made.

## Methodological assessment

The two authors evaluated the quality of the included studies independently, and negotiated or consulted with the superior director to evaluate the divergence. The methodological assessment of included studies was carried out through the risk of bias (ROB) tool provided by the Cochrane Collaboration. The tool consists of seven items including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Each item can be judged as high risk, low risk and unclear risk according to the specific description in the included literature. If there are too many high-risk items or unclear items in the included studies, they will be regarded as low-quality studies and will be excluded or sensitivity analysis will be conducted.

# Statistical analysis

RevMan 5.4 software was used for statistical analysis (8). RR and SMD were respectively used for statistical analysis of dichotomous data and continuous variable, both with 95% confidence interval (CI). The heterogeneity among the included studies was evaluated by  $I^2$ . When  $I^2 > 50\%$ , the heterogeneity was considered to be obvious and the random effect model was selected for analysis. Otherwise, the fixed effect model was adopted. P < 0.05 was considered statistically significant.

### Results

### Identification of relevant literature

The PRISMA flow chart was showed in Figure 1. A total of 25 studies were retrieved from database search and reference list check. Thirteen studies remained after the exclusion of 12 reduplicative studies. Seven studies were excluded after reviewing the title, abstract and full-text. Finally, a total of five RCTs (4, 7, 9–11) with 217 patients were included in this study.

The general information of all included studies was showed in Table 1. The included studies were published between 2005 and 2017. All the studies came from different countries and regions, followed by Iran, Turkey, Egypt, the United States and France. The number of included cases was 33–56, all of which were more than 10. All the cases in the study were minors under the age of 17, including 100 males and 117 females. All pediatric patients received general anesthesia. Sub-Tenon's bupivacaine injection was performed in all the study groups, and placebo or no treatment was used in the control group. Surgery was started 5 min after the




TABLE 1 General characteristics of included studies.

Included study	Location	Cases	Age (years)	Sex (M/F)	Intervention	Comparison	Study design	Outcomes
Talebnejad 2017	Iran	50	12 (8–17)	24/26	Sub-Tenon's bupivacaine injection (0.1 ml, 0.5%)	Normal saline injection (0.1 ml)	RCT <sup>†</sup>	OCR <sup>‡</sup> , VAS <sup>§</sup>
Tuzcu 2015	Turkey	40	10 (5–16)	18/22	Sub-Tenon's bupivacaine injection (0.08 ml/kg, 5%)	No treatment	RCT	OCR, Postoperative verbal rating scale, vomiting, nausea
BakR 2015	Egypt	56	3.3 (2-6)	23/33	Sub-Tenon's bupivacaine injection (0.5%, less than 2.5 mg/kg)	Placebo saline injection	RCT	OCR, pain score, nausea, vomiting
Enyedi 2017	USA	33	4.8 (1-7)	19/14	Sub-Tenon's bupivacaine (0.5 ml, 0.75%)	Balanced salt solution (0.5 ml)	RCT	CHEOPS <sup>5</sup>
Steib 2005	France	38	4.4 (2.5-6)	16/22	Sub-Tenon's bupivacaine injection	Placebo saline injection	RCT	CHEOPS, OCR, PONV

<sup>&</sup>lt;sup>†</sup>RCT, randomized controlled trial.

<sup>&</sup>lt;sup>‡</sup>OCR, oculocardiac reflex.

<sup>&</sup>lt;sup>§</sup>VAS, Visual Analog Scale.

 $<sup>\</sup>mbox{\fontfamily{thm}{\fontfamily{\fontfamily{\fontfamily{thm}{\fontfamily{\font$ 

sub-Tenon's injection in four studies (4, 7, 9, 10), while sub-Tenon's anesthetic was performed at the end of surgery in one (11). All included studies were RCTs.

# Methodological assessment

The methodological quality of included studies was assessed by the ROB tool. As showed in Figure 2, the selection bias, including randomized sequence generation and allocation concealment, was reported and was of low risk in three studies. The blind method for the participants and staff was reported in all studies. Incomplete outcome data and selective reporting were of low risk. The rest items were unclear.

# Outcome measurements

Pain evaluation was reported in five studies. Tuzcu (4) used postoperative verbal rating scale for pain assessment, and no specific value was given. Thus, data from other four studies were extracted and analyzed. The results showed that, compared with placebo, sub-Tenon's bupivacaine injection showed improvement of pain symptom immediately (Figure 3A), half an hour (Figure 3B) after the operation. However, there was no significant difference in pain score between the two groups 60 min after the operation (Figure 3C).

OCR occurrence was recorded in four studies (4, 7, 9, 10) with a total of 211 patients. The incidence of OCR in bupivacaine group was much lower than that in the placebo group (Figure 4).





FIGURE 2
Methodological assessment of included studies by the ROB tool. 1, Random sequence generation; 2, allocation concealment; 3, blinding of participants and personnel; 4, blinding of outcome assessment; 5, incomplete outcome data; 6, selective reporting; 7, other bias.

1	Sub-Tenon's b	upivacaine inj	ection	Placek	o inject	tion		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV. Fixed, 95% CI
Bakr RH 2015	1.77	1.12	27	3.41	1.12	29	61.5%	-1.44 [-2.04, -0.85]	-
Steib A 2005	6.4	8.0	19	9	2	19	38.5%	-1.67 [-2.42, -0.92]	
Total (95% CI)			46			48	100.0%	-1.53 [-2.00, -1.07]	•
Heterogeneity: Chi <sup>2</sup> = 0	0.22, df = 1 (P = $0.6$	$(34); I^2 = 0\%$							
Test for overall effect: 2	Z = 6.45 (P < 0.000	001)							Favours [experimental] Favours [control]
3									
	Sub-Tenon's b				o inject			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD					Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bakr RH 2015	1.66	2	27	3.17	1.04	29	26.0%	-0.94 [-1.50, -0.39]	-
Enyedi LB 2017	6.36	0.97	17	6.58	0.51	16	25.5%	-0.27 [-0.96, 0.41]	<del></del>
Steib A 2005	6	0.7	19	8.4	2.4	19	25.5%	-1.33 [-2.04, -0.62]	_ <del></del>
Talebnejad MR 2017	2.6	0.4	25	4.9	0.45	25	23.0%	-5.32 [-6.54, -4.10]	<del></del>
Total (95% CI)			88			89	100.0%	-1.88 [-3.41, -0.35]	
Heterogeneity: Tau <sup>2</sup> = 2		df = 3 (P < 0.0)	0001); I <sup>2</sup> =	94%				-	_4 _2 0 2 4
Test for overall effect: 2	Z = 2.40 (P = 0.02)								Favours [experimental] Favours [control]
2	Out Towards to			Discort				041 Marris D'//	Old Mary DWarran
Study or Subgroup	Sub-Tenon's b Mean	upivacaine inj SD		Mean	o inject		Weight	Std. Mean Difference IV. Random, 95% CI	Std. Mean Difference IV. Random, 95% CI
Bakr RH 2015	2.11	0.89	27	2.14	0.1	29	26.3%	-0.05 [-0.57, 0.48]	TV, Kalldolli, 95% Cl
Enyedi LB 2017	6.21	1.11	17	6.51	1.1	16	25.9%	-0.26 [-0.95, 0.42]	<del>-</del>
Steib A 2005	6.1	1.11	8	6.8	1.8	17		-0.42 [-1.27, 0.43]	<b>→</b>
Talebnejad MR 2017	2.8	0.35	25	5.9	0.4	25	22.3%	-8.12 [-9.87, -6.37]	-
Total (95% CI)			77			87	100.0%	-2.00 [-4.01, 0.02]	•
Heterogeneity: Tau <sup>2</sup> = 3	3.95; Chi <sup>2</sup> = 76.29,	df = 3 (P < 0.0	0001); I <sup>2</sup> =	96%				-	10 5 10
Test for overall effect: 2	Z = 1.94 (P = 0.05)	,							-10 -5 0 5 10 Favours [experimental] Favours [control]
									Tarours [experimental] Tarours [control]
E 3									




PONV was reported in four studies (4, 7, 9, 10). However, one study (11) did not report nausea and vomiting separately. Therefore, we conducted a pooled analysis of PONV, and then excluded the study and analyzed nausea and vomiting separately. The results showed a tendency of lower incidence of PONV in bupivacaine group (P = 0.06, Figure 5A). When analyzed separately, the incidence of vomiting was higher in the placebo group (P = 0.007, Figure 5B). There was no significant difference in the incidence of nausea between the two groups (P = 0.20, Figure 5C).

Two studies (4, 9) reported additional drug requirement. The number of patients who needed additional drugs in the bupivacaine group was significantly less than that in the placebo group (P = 0.0005, Figure 6).

Length stay recovery room was reported in two studies, but the timing of the reports was different. The average stay time in the recovery room of s bupivacaine group and placebo group was 95 and 145 min respectively (7). In the sub-Tenon's bupivacaine injection group, 8 of 19 cases were in the recovery room 1 h after operation, and only 3 cases at 1.5 h. In the placebo group, 15 of 19 patients were still in the recovery room for 1.5 h (7). The study by Bakr (9) reported similar results. Two hours after operation, 22 out of 29 children in the placebo group were still in the recovery room, while only 4 of the 27 children in the bupivacaine group.

Other outcomes, including chemosis (7) and heart rate deceleration (10), were reported in one study respectively. Although meta-analysis could not be carried out, the results are more favorable to the bupivacaine group.

Study or Subgroup   Events   Total   Events   Total   Weight   M-H. Random. 95% Cl	4	Sub-Tenon's bupivacaine in	njection	Placebo inje	ection		Risk Ratio	Risk	Ratio	
Enyed LB 2017 1 1 17 1 16 11.5% 0.94 [0.06 13.82] Steib A 2005 1 19 18 19 18 19 18.1% 0.06 [0.01, 0.38] Total (95% CI) 83 84 100.0% 0.37 [0.13, 1.06]  Total events 15 44 Heterogeneity: Tau² = 0.65; Chi² = 8.21, df = 3 (P = 0.04); l² = 63%  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 7 19 29.6% 0.14 [0.02, 1.05] Steib A 2005 1 19 7 19 29.6% 0.14 [0.02, 1.05] Total (95% CI) 66 6 8 100.0% 0.39 [0.20, 0.77]  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 7 19 29.6% 0.14 [0.02, 1.05] Total (95% CI) 66 8 20 7 20 29.6% 0.29 [0.07, 1.21]  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 7 19 29.6% 0.14 [0.02, 1.05] Total (95% CI) 66 8 100.0% 0.39 [0.20, 0.77]  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 7 19 29.6% 0.29 [0.07, 1.21]  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 7 19 29.6% 0.29 [0.07, 1.21]  Total (95% CI) 66 6 8 100.0% 0.39 [0.20, 0.77]  Sub-Tenon's bupivacaine injection 5tudy or Subgroup Events Total 19 11 19 20.7% 0.04 [0.00, 6.8]  Total (95% CI) 66 6 8 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 66 6 68 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 67 2 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 67 2 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 67 2 20 4 20 37.9% 0.50 [0.10, 2.43]	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Rand	dom, 95% CI	
Steib A 2005	Bakr RH 2015	9	27	14	29	38.0%	0.69 [0.36, 1.33]	-	†	
Tuzcu K 2015 4 20 11 20 32.5% 0.36 [0.14, 0.95]  Total (95% CI) 83 44 100.0% 0.37 [0.13, 1.06] Total events 15 44 100.0% 0.37 [0.13, 1.06] Heterogeneity: Tau² = 0.65; Chi² = 8.21, df = 3 (P = 0.04); I² = 63% 44 100.0% 0.37 [0.13, 1.06]  Sub-Tenon's bupivacaine injection Events Total Weight M-H. Fixed, 95% CI M-H. Fi	Enyedi LB 2017	1	17	1	16	11.5%	0.94 [0.06, 13.82]		_	
Total (95% CI) 83	Steib A 2005	1	19	18	19	18.1%	0.06 [0.01, 0.38]	-		
Total events 15 Heterogeneity: Tau² = 0.65; Chi² = 8.21, df = 3 (P = 0.04); i² = 63%  Sub-Tenon's bupivacaine injection Study or Subgroup Events Total Events Total Parameters (P = 0.06)  Sub-Tenon's bupivacaine injection Steph A 2005 1 1 19 7 19 29.6% 0.14 [0.02, 1.05]  Total events 9 24 Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29); i² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Placebo injection Study or Subgroup Events Total Weight M-H. Fixed. 95% CI  Risk Ratio Risk Ratio M-H. Fixed. 95% CI  Risk Ratio No.29 (0.07, 1.21)  Total (95% CI) 66 6 8 100.0% 0.39 [0.20, 0.77]  Total events 9 24  Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29); i² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Events Total Veight M-H. Random. 95% CI  Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27]  Total (95% CI) 66 8 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 66 6 68 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 66 6 08 100.0% 0.37 [0.08, 1.70]  Total (95% CI) 67 4 31, df = 2 (P = 0.12); i² = 54%	Tuzcu K 2015	4	20	11	20	32.5%	0.36 [0.14, 0.95]	-	1	
Heterogeneity: Tau² = 0.65; Chi² = 8.21, df = 3 (P = 0.04); i² = 63%  Test for overall effect: Z = 1.85 (P = 0.06)  Sub-Tenon's bupivacaine injection Bakr RH 2015 Color overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Total events  Sub-Tenon's bupivacaine injection Study or Subgroup  Events  Total  Events  Events	Total (95% CI)		83		84	100.0%	0.37 [0.13, 1.06]	•	-	
Sub-Tenon's bupivacaine injection   Study or Subgroup   Events   Total   Events   Total   Events   Total   Events   Total   Events   Eve										
Sub-Tenon's bupivacaine injection   Placebo injection   Study or Subgroup   Events   Total   Events   Total   Weight   M-H. Fixed. 95% Cl   M-H. Fixed. 95% Cl	Heterogeneity: Tau <sup>2</sup> = 0	0.65; $Chi^2 = 8.21$ , $df = 3$ ( $P = 0.6$ )	04); $I^2 = 639$	%				0.005	1 10	200
Sub-Tenon's bupivacaine injection   Study or Subgroup   Events   Total   Events   Total   Events   Total   Weight   M-H. Fixed. 95% Cl   M-H. Fixed. 95% Cl	Test for overall effect: 2	Z = 1.85 (P = 0.06)								200
Study or Subgroup   Events   Total   Events   Total   Weight   M-H. Fixed. 95% Cl								r avours [experimentar]	r avours [control]	
Bakr RH 2015 6 27 10 29 40.8% 0.64 [0.27, 1.53] Steib A 2005 1 19 7 19 29.6% 0.14 [0.02, 1.05] Tuzcu K 2015 2 20 7 20 29.6% 0.29 [0.07, 1.21]  Total (95% CI) 66 6 68 100.0% 0.39 [0.20, 0.77] Total events 9 24 Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29); I² = 18% Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Placebo injection Study or Subgroup Events Total Events Total Weight M-H. Random, 95% CI  Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27] Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69] Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70] Total events 5 19 Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); I² = 54%  Test for everall effect: Z = 1.08 (P = 0.30)	3	Sub-Tenon's bupivacaine	injection	Placebo in	jection		Risk Ratio	Risk	Ratio	
Steib A 2005 1 19 7 19 29.6% 0.14 [0.02, 1.05] Tuzcu K 2015 2 20 7 20 29.6% 0.29 [0.07, 1.21]  Total (95% CI) 66 68 100.0% 0.39 [0.20, 0.77] Total events 9 24  Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29);  ² = 18% Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Favours [experimental] Favours [control]  Study or Subgroup Events Total Events Total Weight M-H. Random. 95% CI  Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27] Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69] Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total events 5 19  Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12);  ² = 54%	Study or Subgroup	Events	Total	Events	Tota	I Weight	M-H. Fixed, 95% CI	M-H, Fixe	ed. 95% CI	
Tuzcu K 2015 2 20 7 20 29.6% 0.29 [0.07, 1.21]  Total (95% CI) 66 68 100.0% 0.39 [0.20, 0.77]  Total events 9 24  Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29);  ² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Favours [experimental] Favours [control]  Sub-Tenon's bupivacaine injection Flacebo injection Favours [experimental] Favours [control]  Risk Ratio Risk Ratio M-H. Random. 95% CI  Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27] Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69] Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total events 5 19  Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12);  ² = 54%	Bakr RH 2015	6	27	10	29	40.8%	0.64 [0.27, 1.53]		_	
Total (95% CI) 66 68 100.0% 0.39 [0.20, 0.77] Total events 9 24  Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29); l² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Favours [experimental]  Study or Subgroup Events Total Events Total Weight M-H. Random, 95% CI  Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27] Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69]  Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total events 5 19  Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); l² = 54%  Total (95% CI) 7 1 20 (P = 0.007)	Steib A 2005	1	19	7	19	29.6%	0.14 [0.02, 1.05]	-	Ī	
Total events 9 24  Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29);  ² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection  Study or Subgroup  Events  Total  Events  Events  Total  Events  Total  Events  Eve	Tuzcu K 2015	2	20	7	20	29.6%	0.29 [0.07, 1.21]	-	<u> </u>	
Heterogeneity: Chi² = 2.44, df = 2 (P = 0.29);  ² = 18%  Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Study or Subgroup Fvents Total Events Total Event										
Test for overall effect: Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine injection Study or Subgroup Events Total Events Tot	Total (95% CI)		66		68	100.0%	0.39 [0.20, 0.77]	•		
Sub-Tenon's bupivacaine injection   Placebo injection   Study or Subgroup   Events   Total   Events   Total   Events   Total   Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); i² = 54%   Favours [experimental]   Favours [control]   Favours [experimental]   Favours [control]   Favours [experimental]   Favours [control]	, ,	9	66	24	68	100.0%	0.39 [0.20, 0.77]	•		
Sub-Tenon's bupivacaine injection	Total events	9 2.44, df = 2 (P = 0.29); l² = 18%		24	68	100.0%	0.39 [0.20, 0.77]	003 01	10	
Sub-Tenon's bupivacaine injection   Placebo	Total events Heterogeneity: Chi <sup>2</sup> = 2			24	68	100.0%	0.39 [0.20, 0.77]			50
Study or Subgroup         Events         Total         Events         Total         Weight         M-H. Random, 95% Cl         M-H. Random, 95% Cl           Bakr RH 2015         3         27         4         29         41.4%         0.81 [0.20, 3.27]           Steib A 2005         0         19         11         19         20.7%         0.04 [0.00, 0.69]           Tuzcu K 2015         2         20         4         20         37.9%         0.50 [0.10, 2.43]           Total (95% Cl)           Total events         5         19           Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); l² = 54%           Total (Part outs)! offect 7 = 1.28 (P = 0.20)	Total events Heterogeneity: Chi <sup>2</sup> = 2			24	68	3 100.0%	0.39 [0.20, 0.77]			50
Bakr RH 2015 3 27 4 29 41.4% 0.81 [0.20, 3.27] Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69] Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70] Total events 5 19 Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); i² = 54%  Test for everall offect: 7 = 1.28 (P = 0.20)	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2	Z = 2.70 (P = 0.007)	6			100.0%	- / -	Favours [experimental]	Favours [control]	50
Steib A 2005 0 19 11 19 20.7% 0.04 [0.00, 0.69] Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70] Total events 5 19 Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); l² = 54%  Total for evental effect: 7 = 1.28 (P = 0.20)	Total events Heterogeneity: Chi² = 2 Test for overall effect:	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in	6 njection	Placebo inje	ection		Risk Ratio	Favours [experimental]	Favours [control]	50
Tuzcu K 2015 2 20 4 20 37.9% 0.50 [0.10, 2.43]  Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total events 5 19  Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12); l² = 54%  Total representation of the chiral state o	Total events Heterogeneity: Chi² = 2 Test for overall effect: 3 Study or Subgroup	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events	6 njection Total	Placebo injo Events	ection Total	Weight	Risk Ratio M-H, Random, 95% CI	Favours [experimental]	Favours [control]	50
Total (95% CI) 66 68 100.0% 0.37 [0.08, 1.70]  Total events 5 19  Heterogeneity: Tau <sup>2</sup> = 0.97; Chi <sup>2</sup> = 4.31, df = 2 (P = 0.12); i <sup>2</sup> = 54%  Total events 7 = 1.39 (P = 0.30)  0.01 0.1 1 10	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3	njection Total 27	Placebo inje Events 4	ection Total 29	Weight 41.4%	Risk Ratio <u>M-H. Random. 95% CI</u> 0.81 [0.20, 3.27]	Favours [experimental]	Favours [control]	50
Total events 5 19 Heterogeneity: Tau² = 0.97; Chi² = 4.31, df = 2 (P = 0.12);  ² = 54%  Total for evently effect: 7 = 1.28 (P = 0.20)  0.01 0.1 1 10	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0	6 njection Total 27 19	Placebo inje Events 4 11	ection Total 29 19	Weight 41.4% 20.7%	Risk Ratio <u>M-H. Random. 95% CI</u> 0.81 [0.20, 3.27] 0.04 [0.00, 0.69]	Favours [experimental]	Favours [control]	50
Heterogeneity: Tau <sup>2</sup> = 0.97; Chi <sup>2</sup> = 4.31, df = 2 (P = 0.12);   <sup>2</sup> = 54%  Text for except of fact   7 = 1.29 (P = 0.20)   1   1   10   10   1   10   10   10	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0	6 njection Total 27 19	Placebo inje Events 4 11	ection Total 29 19	Weight 41.4% 20.7%	Risk Ratio <u>M-H. Random. 95% CI</u> 0.81 [0.20, 3.27] 0.04 [0.00, 0.69]	Favours [experimental]	Favours [control]	50
Toot for everall effect: 7 = 1.39 (P = 0.30)	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005 Tuzcu K 2015 Total (95% CI)	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0 2	njection Total 27 19 20	Placebo inje Events 4 11 4	ection Total 29 19 20	Weight 41.4% 20.7% 37.9%	Risk Ratio <u>M-H. Random, 95% CI</u> 0.81 [0.20, 3.27] 0.04 [0.00, 0.69] 0.50 [0.10, 2.43]	Favours [experimental]	Favours [control]	50
Test for overall effect: Z = 1.28 (P = 0.20)  Favours [experimental] Favours [control]	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005 Tuzcu K 2015 Total (95% CI) Total events	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0 2	njection Total 27 19 20	Placebo inje Events 4 11 4	ection Total 29 19 20	Weight 41.4% 20.7% 37.9%	Risk Ratio <u>M-H. Random, 95% CI</u> 0.81 [0.20, 3.27] 0.04 [0.00, 0.69] 0.50 [0.10, 2.43]	Favours [experimental]	Favours [control]	50
	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005 Tuzcu K 2015  Total (95% CI) Total events Heterogeneity: Tau² = 0	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0 2  5 0.97; Chi² = 4.31, df = 2 (P = 0.	njection Total 27 19 20	Placebo inje Events 4 11 4	ection Total 29 19 20	Weight 41.4% 20.7% 37.9%	Risk Ratio  M-H. Random. 95% CI  0.81 [0.20, 3.27] 0.04 [0.00, 0.69] 0.50 [0.10, 2.43]  0.37 [0.08, 1.70]	Risk M-H. Ranc	Ratio dom, 95% CI	50
	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005 Tuzcu K 2015  Total (95% CI) Total events Heterogeneity: Tau² = 0	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0 2  5 0.97; Chi² = 4.31, df = 2 (P = 0.	njection Total 27 19 20	Placebo inje Events 4 11 4	ection Total 29 19 20	Weight 41.4% 20.7% 37.9%	Risk Ratio  M-H. Random. 95% CI  0.81 [0.20, 3.27] 0.04 [0.00, 0.69] 0.50 [0.10, 2.43]  0.37 [0.08, 1.70]	Favours [experimental]  Risk M-H. Ranc  0.01 0.1	Ratio tom. 95% CI	
RE 5	Total events Heterogeneity: Chi² = 2 Test for overall effect: 2  Study or Subgroup Bakr RH 2015 Steib A 2005 Tuzcu K 2015  Total (95% CI) Total events Heterogeneity: Tau² = 0	Z = 2.70 (P = 0.007)  Sub-Tenon's bupivacaine in  Events  3 0 2  5 0.97; Chi² = 4.31, df = 2 (P = 0.	njection Total 27 19 20	Placebo inje Events 4 11 4	ection Total 29 19 20	Weight 41.4% 20.7% 37.9%	Risk Ratio  M-H. Random. 95% CI  0.81 [0.20, 3.27] 0.04 [0.00, 0.69] 0.50 [0.10, 2.43]  0.37 [0.08, 1.70]	Favours [experimental]  Risk M-H. Ranc  0.01 0.1	Ratio tom. 95% CI	



# Discussion

Adjuvant local anesthesia has been proved to reduce postoperative pain and the incidence of OCR in pediatric ophthalmic surgery (12). The role of sub-Tenon's bupivacaine injection in cataract surgery has been confirmed (13), but its role in children strabismus surgery is still controversial. Therefore, a total of 5 RCTs and 217 patients were included and analyzed. The results showed that sub-Tenon's bupivacaine injection could reduce the short-term postoperative pain, and the analgesic effect gradually weakened with the extension of time. Meanwhile, it could reduce the incidence of OCR and vomiting, and it also had a certain effect on additional drug requirement and rapid recovery.

In this meta-analysis, all included studies were double-blind RCTs. This kind of rigorous and prospective study design can reduce the bias caused by subjective judgment and other factors, reduce the heterogeneity, and improve the credibility of the conclusion. All the studies were from different countries and regions, which minimized the bias caused by different ethnic and medical conditions.

Regional anesthesia has been proved to reduce postoperative pain and the use of postoperative analgesics. Sub-Tenon's bupivacaine injection under direct visualization is a relatively safe method of local anesthesia (4, 14), As a long-acting local anesthetic, bupivacaine can provide relatively long-term (3–3.5 h) analgesic effect (12). However, in this study, the analgesic effect was only maintained until 30 min after operation, and there was no significant difference in pain score between the two groups at 1 h after operation. On the one hand, the conclusion is more conservative because of the heterogeneity between studies, and on the other hand, it may be related to the time and dose of administration.

OCR refers to a 20% decrease in heart rate or new arrhythmia during eye muscle traction, which occurs in 90% of strabismus surgery (12). Several methods have been proposed to minimized the incidence of OCR. However, the effect of all these methods was limited. Sub-Tenon's bupivacaine injection was confirmed to be effective in reducing the incidence of OCR and PONV (7, 9, 10). However, another study by Tuzcu et al. (4) found that the incidence of OCR and PONV were less commonly for patients with sub-Tenon's bupivacaine injection, but the difference was not statistically significant. In this study, the incidence of OCR and PONV was lower in the experimental group, but there was no significant difference in PONV. When analyzing the data, we found that there was non-negligible heterogeneity of the data in the literature. Some studies only counted OCR, and some mentioned nausea/vomiting. Therefore, in order to make the study more objective and not omit important

complications, we conducted statistical analysis on OCR and nausea/vomiting respectively. Interestingly, when the incidence of nausea and vomiting were analyzed separately, the incidence of vomiting in the bupivacaine group was lower, and the difference was statistically significant. Therefore, we speculate that the reason for no significant difference in PONV may be the high heterogeneity ( $I^2 = 63\%$ ) among the included studies.

Two articles (4, 9) reported the data of additional systemic analgesia requirements, however, both articles did not report which specific drugs were used. In order to minimize the possible bias of PONV caused by opioids use, we excluded both articles in the analysis of PONV. The data of PONV in the remaining two articles (7, 11) were highly heterogeneous, and there was no significant difference using the random effect model. This suggests that the additional use of anesthetic drug may affect PONV, but it does not change the trend of this outcome. The concentration and volume of bupivacaine used in included studies were various. 0.5% bupivacaine is the most commonly used, and the volume varies from 0.1 to 3 ml. This difference is related to the different habits of deach surgeon. It needs further study to determine which concentration and volume are more appropriate.

The concentration and volume of bupivacaine used in included studies were various. 0.5% bupivacaine was the most commonly used, and the volume varied from 0.1 to 3 ml. This difference is related to the different habits of different surgeons. Which concentration and volume are more appropriate needs further study.

The sub-Tenon's bupivacaine injection has few major adverse reactions when applied to children's strabismus surgery. But there have been some sporadic reports of extraocular muscle injury, hemorrhage and globe perforation (15, 16). For children, other minor complications such as conjunctival hemorrhage, petechiae and chemosis may be more common. However, among all 217 patients included in this study, only one patient with chemosis was reported and no major complication was reported. It indicated that the technique is safe for strabismus surgery in children.

This is a secondary analysis based on published data. There are some shortcomings that should not be ignored. Firstly, Although the studies included are well-designed RCTs, there are still some heterogeneities between the studies, such as the age difference of the included patients, the choice of different pain scales and the different dosage of bupivacaine injection, which may have certain impacts on the final results. For strabismus surgery, the degree of pain and the incidence of OCR may be different with different surgical methods. However, several included literatures did not report the details of surgery, and the methodology focused on the

description of anesthesia. Therefore, the clinical heterogeneity among the included studies should not be ignored. Caution is required in clinical practice of the conclusion. Secondly, the included studies focused on the pain, OCR and drug requirement in the operating room, but did not involve the operation technique, postoperative visual rehabilitation and follow-up, which need further supplement in future research. Finally, the number of cases included in this study is 217, which is not a large sample size. When the sample size is further expanded, it is not known whether the conclusion of this paper will change.

Meta analysis will exaggerate the positive research results by excluding the gray literature, leading to decision-making errors. In order to ensure that the results of meta-analysis are more comprehensive and objective, and to overcome publication bias, it is recommended to include gray literature in meta-analysis. In this study, only published studies were included, so we re-searched several commonly used gray literature websites (GreyNet International: http://www.greynet.org/, Grey Literature Report: http://www.greylit.org/, Open Grey: https://opengrey.eu/), but no literature that meets the inclusion criteria of this paper was found. Therefore, the publication bias of this article is acceptable.

### Conclusion

Sub-Tenon's bupivacaine injection can relieve short-term postoperative pain, reduce the incidence of OCR and vomiting, and reduce the use of drugs in strabismus surgery.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

## References

- 1. Lambert SR. Population-based incidence of strabismus: why is it important? JAMA Ophthalmol. (2017) 135:1053–4. doi: 10.1001/jamaophthalmol.2017.3123
- 2. Choi SR, Park SW, Lee JH, Lee SC, Chung CJ. Effect of different anesthetic agents on oculocardiac reflex in pediatric strabismus surgery. *J Anesth.* (2009) 23:489–93. doi: 10. 1007/s00540-009-0801-0
- 3. Waldschmidt B, Gordon N. Anesthesia for pediatric ophthalmologic surgery. J AAPOS. (2019) 23:127–31. doi: 10.1016/j.jaapos.2018.10.017
- 4. Tuzcu K, Coskun M, Tuzcu EA, Karcioglu M, Davarci I, Hakimoglu S, et al. Effectiveness of sub-tenon's block in pediatric strabismus surgery. *Braz J Anesthesiol.* (2015) 65:349–52. doi: 10.1016/j.bjane.2014.02.003
- 5. Chua MJ, Lersch F, Chua AWY, Kumar CM, Eke T. Sub-Tenon's anaesthesia for modern eye surgery-clinicians' perspective, 30 years after re-introduction. *Eye.* (2021) 35:1295–304. doi: 10.1038/s41433-021-01412-5
- 6. Lewis H, James I. Update on anaesthesia for paediatric ophthalmic surgery. BJA Educ. (2021) 21:32–8. doi: 10.1016/j.bjae.2020.09.002
- 7. Steib A, Karcenty A, Calache E, Franckhauser J, Dupeyron JP, Speeg-Schatz C. Effects of subtenon anesthesia combined with general anesthesia on perioperative analgesic requirements in pediatric strabismus surgery. *Reg Anesth Pain Med.* (2005) 30:478–83. doi: 10.1016/j.rapm.2005.04.011
- $8.\ Review manager (RevMan)$  [computer program]. Version 5.4.1 ed.: The Cochrane Collaboration (2020).

# **Author contributions**

KM was responsible for designing the study. ZW and LZ was responsible for literature search, data extraction. WQ, DX and JB performed methodological assessment and statistical analysis. ZW draft the manuscript. KM and LZ contributed prepared the manuscript. All authors contributed to the article and approved the submitted version.

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2023.1105186/full#supplementary-material.

- 9. Bakr RH, Abdelaziz HM. Subtenon bupivacaine injection for postoperative pain relief following pediatric strabismus surgery: a randomized controlled double blind trial. *Middle East J Anaesthesiol.* (2015) 23:91–9. PMID: 26121900
- 10. Talebnejad MR, Khademi S, Ghani M, Khalili MR, Nowroozzadeh MH. The effect of sub-tenon's bupivacaine on oculocardiac reflex during strabismus surgery and postoperative pain: a randomized clinical trial. *J Ophthalmic Vis Res.* (2017) 12:296–300. doi: 10.4103/jovr.jovr\_66\_16
- 11. Enyedi LB, Wallace DK, de L Dear G. A double-masked randomized trial of postoperative local anesthetic for pain control in pediatric strabismus surgery. *J Aapos*. (2017) 21:107–11. doi: 10.1016/j.jaapos.2017.03.005
- 12. Jean YK, Kam D, Gayer S, Palte HD, Stein A. Regional anesthesia for pediatric ophthalmic surgery: a review of the literature. *Anesth Analg.* (2020) 130:1351–63. doi: 10.1213/ANE.0000000000004012
- 13. Wu S, Tang KC. Advanced subconjunctival anesthesia for cataract surgery. *Asia Pac J Ophthalmol.* (2018) 7:296–300. doi: 10.22608/APO.2018231
- 14. Ibrahim AN, Shabana T. Sub-Tenon's injection versus paracetamol in pediatric strabismus surgery. Saudi J Anaesth. (2017) 11:72–6. doi: 10.4103/1658-354X.197349
- 15. Singh SR, Dogra M, Singh R, Dogra MR. Accidental globe perforation during posterior sub-tenon's injection of triamcinolone acetonide. *Ophthalmic Surg Lasers Imaging Retina*. (2019) 50:466–7. doi: 10.3928/23258160-20190703-11
- 16. Jaycock PD, Mather CM, Ferris JD, Kirkpatrick JN. Rectus muscle trauma complicating sub-tenon's local anaesthesia. Eye. (2001) 15:583–6. doi: 10.1038/eye.2001.189